Esmo 2021 – Astra coasts towards a new lung cancer combo
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Esmo 2021 – Opdivo’s glimmer of hope in front-line head and neck cancer
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Esmo 2021 – Keytruda challenges Jemperli and adjuvant melanoma
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
World Lung 2021 – treme stands up to scrutiny
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
Sanofi’s Principia purchase fails its first test
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
Novartis pushes on with iscalimab after transplant disappointment
The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.
Jaks capped in arthritis – but the FDA might not be finished
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
Tecentriq pullout dominates the latest PD-(L)1 moves
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.
